| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | SARS-CoV-2 |
| Clinical data | |
| Trade names | Kavigale |
| Other names | AZD-3152 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Sipavibart, sold under the brand nameKavigale, is amedication used for the prevention ofCOVID-19 in people who are immunocompromised.[1] Sipavibart is a recombinant human IgG1monoclonal antibody that provides passive immunization againstSARS-CoV-2 by binding itsspike protein receptor binding domain.[1][3]
Sipavibart was authorized for medical use in the European Union in January 2025.[1][2]
Sipavibart isindicated for the pre-exposure prophylaxis of COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments.[1][2]
In December 2024, theCommittee for Medicinal Products for Human Use of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID-19 in immunocompromised people aged twelve years of age and older.[1] Kavigale was reviewed under the EMA's accelerated assessment program.[1] The applicant for this medicinal product is AstraZeneca AB.[1] Sipavibart was authorized for medical use in the European Union in January 2025.[1][2]
Sipavibart is theinternational nonproprietary name.[4]
Sipavibart is sold under the brand name Kavigale.[1][2]
.svg)
